Dermatology Times: July 28, 2025

12345678910111213141516
Across
  1. 6. Autoimmune disease reviewed in a “Rheum With a View” session focusing on cutaneous manifestations at DERM 2025.
  2. 8. IL‑23 inhibitor with positive phase 3 results reported for psoriatic arthritis.
  3. 9. Biologic that Jacob Thyssen, PhD, highlighted as promising for hard‑to‑treat hand eczema.
  4. 11. Investigational psoriasis agent with positive phase 3 results in high‑impact areas presented at DERM 2025.
  5. 12. Castle Biosciences’ melanoma test that earned FDA Breakthrough Device designation for risk stratification.
  6. 14. (Abbreviation)Lymphoma in which pruritus severity correlated with quality of life in this week’s Journal Digest.
  7. 15. PDE4 inhibitor cream being studied for safety and efficacy in infants with atopic dermatitis in the INTEGUMENT-INFANT trial.
  8. 16. Biologic shown effective for genital and scalp psoriasis in the UnlIMMited poster at DERM 2025.
Down
  1. 1. TYK2 inhibitor with an FDA‑accepted sNDA for treating active psoriatic arthritis.
  2. 2. (Abbreviation) “Forever chemicals” Michelle Hure, MD, warned may pose clinical concerns in dermatology products.
  3. 3. BTK inhibitor demonstrating swift CSU activity score reductions at Elevate‑Derm Summer.
  4. 4. Aesthetic agents whose broader impact was explored using patient‑reported outcomes by Steven Dayan, MD.
  5. 5. Cancer type where gene expression profiling is transforming management of recurrence risk and treatment decisions.
  6. 7. Pan-JAK inhibitor cream newly FDA‑approved as the first approved therapy in the US for chronic hand eczema in adults.
  7. 10. testing (2 words) Diagnostic step Walter Liszewski, MD, highlighted for tailoring atopic dermatitis care.
  8. 13. (Abbreviation) Global health body whose new resolution on skin diseases aims to close care gaps worldwide.